Temozolomide hexadecyl ester targeted plga nanoparticles for drug-resistant glioblastoma therapy via intranasal administration

Temozolomide hexadecyl ester targeted plga nanoparticles for drug-resistant glioblastoma therapy via intranasal administration

Introduction: Temozolomide (TMZ) is the first-line drug for glioblastoma (GBM), but it is limited in clinical use due to the drug resistance, poor brain targeting, and side effects. Temozolomide hexadecyl ester (TMZ16e), a TMZ derivative with high lipophilicity, membrane permeability, and high anti-...

Full description

Bibliographic Details
Main Authors: Siqi Wang, Yawen Yu, Aiping Wang, Xinliu Duan, Yuchen Sun, Liangxiao Wang, Liuxiang Chu, Yanan Lv, Nan Cui, Xuesong Fan, Chunjie Sha, Lixiao Xu, Kaoxiang Sun
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Pharmacology
Subjects:
glioblastoma
drug resistance
temozolomide hexadecyl ester
anti-EphA3
nanoparticles
intranasal administration
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.965789/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.965789/full

Similar Items